AEON Biopharma, Inc.

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutic formulations of botulinum toxin complex, targeting neurological and other therapeutic indications. The company pursued a go-public transaction with Priveterra Acquisition Corp, a SPAC that completed its IPO in 2021 under the ticker PMGM and was sponsored by Priveterra Holdings. AEON filed this Form 10-Q with the SEC on November 14, 2022, covering its operations during the quarter ended September 30, 2022, while the de-SPAC process was advancing. The company operates in the biopharmaceuticals sector within the broader healthcare industry. Sign up for SpacDesk to access full filing histories, SPAC merger timelines, and sponsor data for AEON Biopharma and hundreds of other transactions.